HK1079437A1 - Topically applicable pharmaceutical preparation - Google Patents

Topically applicable pharmaceutical preparation

Info

Publication number
HK1079437A1
HK1079437A1 HK05111481.8A HK05111481A HK1079437A1 HK 1079437 A1 HK1079437 A1 HK 1079437A1 HK 05111481 A HK05111481 A HK 05111481A HK 1079437 A1 HK1079437 A1 HK 1079437A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical preparation
topically applicable
applicable pharmaceutical
topically
administering
Prior art date
Application number
HK05111481.8A
Other languages
English (en)
Inventor
Christina Bolle
Rudolf Linder
Original Assignee
Nycomed Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Gmbh filed Critical Nycomed Gmbh
Publication of HK1079437A1 publication Critical patent/HK1079437A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F41—WEAPONS
    • F41B—WEAPONS FOR PROJECTING MISSILES WITHOUT USE OF EXPLOSIVE OR COMBUSTIBLE PROPELLANT CHARGE; WEAPONS NOT OTHERWISE PROVIDED FOR
    • F41B5/00—Bows; Crossbows
    • F41B5/12—Crossbows
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F41—WEAPONS
    • F41B—WEAPONS FOR PROJECTING MISSILES WITHOUT USE OF EXPLOSIVE OR COMBUSTIBLE PROPELLANT CHARGE; WEAPONS NOT OTHERWISE PROVIDED FOR
    • F41B5/00—Bows; Crossbows
    • F41B5/12—Crossbows
    • F41B5/123—Compound crossbows
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F41—WEAPONS
    • F41B—WEAPONS FOR PROJECTING MISSILES WITHOUT USE OF EXPLOSIVE OR COMBUSTIBLE PROPELLANT CHARGE; WEAPONS NOT OTHERWISE PROVIDED FOR
    • F41B5/00—Bows; Crossbows
    • F41B5/14—Details of bows; Accessories for arc shooting
    • F41B5/1442—Accessories for arc or bow shooting
    • F41B5/1469—Bow-string drawing or releasing devices

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • General Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK05111481.8A 2002-05-28 2005-12-14 Topically applicable pharmaceutical preparation HK1079437A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10223828 2002-05-28
EP02011830 2002-05-28
DE10311613 2003-03-14
PCT/EP2003/005524 WO2003099334A1 (en) 2002-05-28 2003-05-27 Topically applicable pharmaceutical preparation

Publications (1)

Publication Number Publication Date
HK1079437A1 true HK1079437A1 (en) 2006-04-07

Family

ID=29587313

Family Applications (2)

Application Number Title Priority Date Filing Date
HK05111481.8A HK1079437A1 (en) 2002-05-28 2005-12-14 Topically applicable pharmaceutical preparation
HK05111628.2A HK1079445A1 (en) 2002-05-28 2005-12-16 Ophthalmological use of roflumilast for the treatment of diseases of the eye

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK05111628.2A HK1079445A1 (en) 2002-05-28 2005-12-16 Ophthalmological use of roflumilast for the treatment of diseases of the eye

Country Status (33)

Country Link
US (7) US20060084684A1 (xx)
EP (3) EP1511516B1 (xx)
JP (3) JP5652983B2 (xx)
KR (2) KR101307093B1 (xx)
CN (3) CN100490804C (xx)
AT (2) ATE485821T1 (xx)
AU (2) AU2003232828B2 (xx)
BR (2) BR0311339A (xx)
CA (2) CA2486917C (xx)
CY (2) CY1110312T1 (xx)
DE (2) DE60325354D1 (xx)
DK (3) DK1511516T3 (xx)
EA (2) EA010416B1 (xx)
ES (3) ES2354971T3 (xx)
HK (2) HK1079437A1 (xx)
HR (1) HRP20041211B1 (xx)
HU (1) HUE039709T2 (xx)
IL (3) IL164935A (xx)
IS (1) IS2639B (xx)
LT (1) LT2020243T (xx)
MA (1) MA27813A1 (xx)
ME (1) ME00565A (xx)
MX (2) MXPA04011612A (xx)
NO (2) NO334882B1 (xx)
NZ (3) NZ536920A (xx)
PL (3) PL211870B1 (xx)
PT (3) PT1511516E (xx)
RS (1) RS51104B (xx)
SI (2) SI1511516T1 (xx)
TR (1) TR201815573T4 (xx)
UA (2) UA81910C2 (xx)
WO (2) WO2003099278A1 (xx)
ZA (2) ZA200408649B (xx)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6872382B1 (en) 2001-05-21 2005-03-29 Alcon, Inc. Use of selective PDE IV inhibitors to treat dry eye disorders
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
SI1511516T1 (sl) * 2002-05-28 2009-06-30 Nycomed Gmbh Topično uporaben farmacevtski pripravek
MXPA05003063A (es) 2002-09-20 2005-05-27 Alcon Inc Uso de inhibidores de la sintesis de citosina para el tratamiento de trastornos de ojos secos.
FR2851247B1 (fr) 2003-02-19 2007-06-29 Exonhit Therapeutics Sa Methodes et compositions pour le traitement de pathologies degeneratives oculaires
KR101179012B1 (ko) 2003-03-10 2012-09-03 니코메드 게엠베하 로플루미라스트 신규한 제조 방법
JP2007517893A (ja) * 2004-01-10 2007-07-05 バイオリピッド インコーポレイテッド 脂質組成物及び該脂質組成物の使用方法
DE102004046236A1 (de) * 2004-09-22 2006-03-30 Altana Pharma Ag Arzneimittelzubereitung
DE102004046235A1 (de) * 2004-09-22 2006-03-30 Altana Pharma Ag Arzneimittelzubereitung
CA2599376C (en) * 2005-03-08 2014-05-13 Nycomed Gmbh Roflumilast for the treatment of diabetes mellitus
AU2006224619B2 (en) * 2005-03-16 2012-06-07 Takeda Gmbh Taste masked dosage form containing roflumilast
CN101193634A (zh) * 2005-06-09 2008-06-04 参天制药株式会社 罗氟司特滴眼液
MX2008010774A (es) 2006-02-21 2008-09-01 Eisai R&D Man Co Ltd Derivados de 4-(3-benzoilaminofenil)-6, 7-dimetoxi-2-metilaminoqui nazolina.
EP2123641A4 (en) 2007-02-16 2011-06-22 Eisai R&D Man Co Ltd CRYSTAL, AMORPHOUS FORM AND METHYL N-Ý3- (6,7-DIMETHOXY-2-METHYLAMINOQUINAZOLINE-4-YL) PHENYLENE TEREPHTALIC ACID SALT
JP5060561B2 (ja) 2007-08-17 2012-10-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 新規外用剤
US8492543B2 (en) 2007-08-17 2013-07-23 Eisai R&D Management Co., Ltd. Method for producing quinazoline derivative
AU2010318687B2 (en) 2009-10-30 2016-02-25 Nestec S.A. Methods for maintaining eye health and ameliorating opthalmic maladies in canines
ES2408132B1 (es) * 2010-09-08 2014-04-04 Universidad Miguel Hernández De Elche Composición farmacéutica para el tratamiento de la epífora.
ES2377785B2 (es) 2010-09-08 2012-09-26 Universidad Miguel Hernández De Elche Composición farmacéutica para el tratamiento del ojo seco.
WO2012121988A2 (en) * 2011-03-07 2012-09-13 Celgene Corporation Methods for treating diseases using isoindoline compounds
CN102793684B (zh) * 2011-05-26 2016-02-17 杭州赛利药物研究所有限公司 罗氟司特液体制剂及其制备方法
EA201400064A1 (ru) * 2011-06-28 2014-05-30 Байер Хелфкеэ Ллк Офтальмологическая фармацевтическая композиция для местного применения, которая содержит регорафениб
WO2013155123A1 (en) * 2012-04-10 2013-10-17 Georgia State University Research Foundation, Inc. Compositions and methods for treating otitis media and other conditions with inhibitors of cyld
WO2014012954A1 (en) 2012-07-18 2014-01-23 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma
CN103570610B (zh) * 2012-07-18 2017-08-11 重庆华邦制药有限公司 一种罗氟司特微粒的制备方法
KR20210010958A (ko) * 2012-11-08 2021-01-28 리젠 파마슈티컬스 소시에떼 아노님 Pde4 억제제 및 pi3 델타 또는 이중 pi3 델타-감마 키나아제 억제제를 함유하는 약제학적 조성물
AU2014307803A1 (en) 2013-08-16 2016-03-10 Universiteit Maastricht Treatment of cognitive impairment with PDE4 inhibitor
CN105434328A (zh) * 2014-09-01 2016-03-30 天津药物研究院有限公司 一种含罗氟司特固体分散体的固体制剂及其制备方法
EP3210974B1 (en) * 2014-10-24 2020-01-29 Hisamitsu Pharmaceutical Co., Inc. Prodrug of roflumilast
CN104997959A (zh) * 2015-08-21 2015-10-28 蔡宇平 一种用于治疗睑板腺囊肿的中药
CN106148528B (zh) * 2016-07-11 2019-10-01 赵晨 一种遗传性Usher综合征的致病突变及其检测试剂
US9895359B1 (en) 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast
US11129818B2 (en) 2017-06-07 2021-09-28 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having improved delivery and plasma half life
US11534493B2 (en) * 2017-09-22 2022-12-27 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
CN108283620A (zh) * 2018-03-13 2018-07-17 兆科药业（广州）有限公司 一种磷酸二酯酶-4抑制剂的局部药物组合物及其制备方法
WO2019236374A2 (en) * 2018-06-04 2019-12-12 Arcutis, Inc. Method and formulation for improving roflumilast skin penetration lag time
KR102117525B1 (ko) * 2018-07-09 2020-06-01 건양대학교 산학협력단 Pde4b 저해제를 유효성분으로 함유하는 만성 부비동염에서의 비용종 발생의 예방 및 치료용 약학 조성물
US20200155524A1 (en) * 2018-11-16 2020-05-21 Arcutis, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
KR20220134617A (ko) 2020-01-31 2022-10-05 아큐티스 바이오테라퓨틱스, 인크. 개선된 전달 및 혈장 반감기를 갖는 국소 로플루밀라스트 제형
MX2022008735A (es) * 2020-05-07 2022-09-19 Arcutis Biotherapeutics Inc Tratamiento de condiciones de la piel usando tensioactivos anionicos de alta temperatura de krafft.
WO2022169615A1 (en) 2021-02-05 2022-08-11 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
CN116867480A (zh) * 2021-02-10 2023-10-10 洛利克斯治疗有限公司 眼部递送罗氟司特的方法
US20220249451A1 (en) * 2021-02-10 2022-08-11 Hawkeye Therapeutics Inc. Methods for ophthalmic delivery of roflumilast
WO2022256412A2 (en) * 2021-06-01 2022-12-08 Eyedea Bio, Llc Extended release drug delivery system for ocular drugs and methods of use
US20230090417A1 (en) * 2021-09-22 2023-03-23 Iolyx Therapeutics, Inc. Methods of treating ocular inflammatory diseases
US20240108609A1 (en) 2022-09-15 2024-04-04 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4753945A (en) * 1986-02-19 1988-06-28 Eye Research Institute Of Retina Foundation Stimulation of tear secretion with phosphodiesterase inhibitors
US5011843A (en) * 1988-05-31 1991-04-30 Iolab Corporation Treatment of glaucoma using phosphodiesterase inhibitors
US5891904A (en) * 1992-09-14 1999-04-06 Wolf-Georg Forssmann Use of inhibitors of phosphodiesterase IV
CA2165192C (en) * 1993-07-02 2001-04-24 Hermann Amschler Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors
WO1995004551A1 (fr) * 1993-08-10 1995-02-16 Fujisawa Pharmaceutical Co., Ltd. Preparation absorbable par voie percutanee
ZA954599B (en) * 1994-06-07 1996-01-26 Allergan Inc Stable gel formulation for topical treatment of skin conditions
KR20010075287A (ko) * 1998-09-29 2001-08-09 후지야마 아키라 피리도피라진 화합물의 신규한 염 및 그의 결정
US6395746B1 (en) * 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
US20020006418A1 (en) * 1998-10-13 2002-01-17 John Kung Composition to enhance permeation of topical skin agents
CA2364258C (en) 1999-03-10 2008-12-30 Byk Gulden Lomberg Chemische Fabrik Gmbh 3-cyclopropylmethoxy-4-difluoromethoxy-n-(3,5-dichloropyrid-4-yl)benzamide in the treatment of multiple sclerosis
US6174878B1 (en) * 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain
AP2002002446A0 (en) * 1999-10-29 2002-03-31 Smithkline Beecham Corp Method for administering a phosphodiesterase 4 inhibitor.
IL150486A0 (en) * 2000-01-31 2002-12-01 Pfizer Prod Inc Pyrimidine carboxamides useful as inhibitors of pde4 isozymes
WO2001060358A1 (en) * 2000-02-16 2001-08-23 University Of Nebraska Medical Center Method and compositions for treating fibrotic diseases
JP2003534328A (ja) * 2000-05-25 2003-11-18 メルク フロスト カナダ アンド カンパニー フルオロアルコキシ置換ベンズアミドジクロロピリジニルｎ−オキシドｐｄｅ４阻害剤
CA2427814C (en) * 2000-11-07 2009-06-02 Merck & Co., Inc. A combination of a pde4 inhibitor and a leukotriene antagonist in the treatment of bronchial and respiratory disorders
UA77656C2 (en) * 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
US6872382B1 (en) * 2001-05-21 2005-03-29 Alcon, Inc. Use of selective PDE IV inhibitors to treat dry eye disorders
US20030092706A1 (en) * 2001-11-09 2003-05-15 Johannes Barsig Combination
SI1511516T1 (sl) * 2002-05-28 2009-06-30 Nycomed Gmbh Topično uporaben farmacevtski pripravek

Also Published As

Publication number Publication date
JP5683538B2 (ja) 2015-03-11
KR20050014844A (ko) 2005-02-07
US20140303215A1 (en) 2014-10-09
PL372082A1 (en) 2005-07-11
CN1655782A (zh) 2005-08-17
PL212134B1 (pl) 2012-08-31
CN101491520B (zh) 2011-03-16
EP2020243A1 (en) 2009-02-04
BR0311339A (pt) 2005-03-22
EP1511481A1 (en) 2005-03-09
PT1511516E (pt) 2009-02-20
US20060084685A1 (en) 2006-04-20
UA88523C2 (ru) 2009-10-26
NO334916B1 (no) 2014-07-14
AU2003240719A1 (en) 2003-12-12
TR201815573T4 (tr) 2018-11-21
KR20110122230A (ko) 2011-11-09
LT2020243T (lt) 2018-11-12
HRP20041211B1 (hr) 2013-06-30
EP1511516A1 (en) 2005-03-09
RS101404A (xx) 2007-02-05
MXPA04011612A (es) 2005-03-07
US20060084684A1 (en) 2006-04-20
CN101491520A (zh) 2009-07-29
CY1121133T1 (el) 2019-12-11
IL164935A0 (en) 2005-12-18
IL209657A0 (en) 2011-02-28
CN1655823B (zh) 2010-05-26
PT1511481E (pt) 2011-01-14
NZ537308A (en) 2009-09-25
PL397021A1 (pl) 2012-03-26
HK1079445A1 (en) 2006-04-07
IS7612A (is) 2004-12-23
DK2020243T3 (en) 2018-11-19
SI2020243T1 (sl) 2018-11-30
IS2639B (is) 2010-06-15
BR0311337A (pt) 2005-03-15
WO2003099334A1 (en) 2003-12-04
ATE485821T1 (de) 2010-11-15
NZ553731A (en) 2007-07-27
MXPA04011528A (es) 2005-02-14
EA200401517A1 (ru) 2005-06-30
ZA200409584B (en) 2006-05-31
KR101307093B1 (ko) 2013-09-11
US20190029956A1 (en) 2019-01-31
EA010416B1 (ru) 2008-08-29
ES2354971T3 (es) 2011-03-21
HUE039709T2 (hu) 2019-01-28
MA27813A1 (fr) 2006-04-03
CN1655823A (zh) 2005-08-17
NO20045656L (no) 2004-12-27
PT2020243T (pt) 2018-11-09
DK1511481T3 (da) 2011-01-24
US20110313005A1 (en) 2011-12-22
CA2486917A1 (en) 2003-12-04
IL164935A (en) 2010-12-30
CN100490804C (zh) 2009-05-27
CA2486910C (en) 2011-11-29
ATE417628T1 (de) 2009-01-15
AU2003232828A1 (en) 2003-12-12
EP2020243B1 (en) 2018-08-15
UA81910C2 (uk) 2008-02-25
EP1511516B1 (en) 2008-12-17
RS51104B (sr) 2010-10-31
NO20045506L (no) 2004-12-16
IL165065A0 (en) 2005-12-18
AU2003232828B2 (en) 2010-06-24
NO334882B1 (no) 2014-06-30
EP1511481B1 (en) 2010-10-27
JP2005529928A (ja) 2005-10-06
JP2012229245A (ja) 2012-11-22
HRP20041211A2 (hr) 2006-04-30
DE60334692D1 (de) 2010-12-09
JP2005529930A (ja) 2005-10-06
ME00565A (en) 2011-12-20
JP5652983B2 (ja) 2015-01-14
US20080280958A1 (en) 2008-11-13
SI1511516T1 (sl) 2009-06-30
EA020569B1 (ru) 2014-12-30
PL372095A1 (en) 2005-07-11
IL165065A (en) 2010-11-30
PL211870B1 (pl) 2012-07-31
DE60325354D1 (de) 2009-01-29
CA2486910A1 (en) 2003-12-04
AU2003240719B2 (en) 2009-12-10
ZA200408649B (en) 2007-12-27
NZ536920A (en) 2007-04-27
WO2003099278A1 (en) 2003-12-04
CA2486917C (en) 2011-11-22
EA200702588A1 (ru) 2008-08-29
CY1110312T1 (el) 2015-01-14
ES2693094T3 (es) 2018-12-07
DK1511516T3 (da) 2009-04-06
US20210116207A1 (en) 2021-04-22
ES2319517T3 (es) 2009-05-08

Similar Documents

Publication Publication Date Title
CY1121133T1 (el) Τοπικα εφαρμοσιμο φαρμακευτικο παρασκευασμα
AU1708202A (en) Organic compounds
YU58103A (sh) Farmaceutski preparati, dozirane forme i postupci za oralnu primenu epotilona
CA2301017A1 (en) Use of propyl gallate to increase bioavailability of orally administered pharmaceutical compounds
MY135646A (en) Indolyl derivatives
IL108246A0 (en) Nonatetraenoic acid derivates, their preparation and pharmaceutical compositions containing them
ECSP045447A (es) Preparación farmacéutica que se puede aplicar por vía tópica

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20160527